カテゴリー： Market Monitor Global, 世界, 医療/バイオ

脂質代謝異常症治療薬の世界市場見通し2023年-2029年

◆英語タイトル：Drugs for Lipid Metabolism Disease Market, Global Outlook and Forecast 2023-2029
	◆商品コード：MMG23LY8494 ◆発行会社（リサーチ会社）：Market Monitor Global ◆発行日：2023年7月（※2025年版があります。お問い合わせください。） ◆ページ数：72 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後2-3営業日） ◆調査対象地域：グローバル ◆産業分野：医薬品＆ヘルスケア

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥468,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥608,400	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥702,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Global Drugs for Lipid Metabolism Disease Market 調査レポートは次の情報を含め、グローバルにおけるの脂質代謝異常症治療薬市場規模と予測を収録しています。・世界の脂質代謝異常症治療薬市場：売上、2018年-2023年、2024年-2029年
・世界の脂質代謝異常症治療薬市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の脂質代謝異常症治療薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。アメリカ市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「OTC」セグメントは今後6年間、000%の年平均成長率で2029年までに000Mドルに成長すると予測されています。

脂質代謝異常症治療薬のグローバル主要企業は、Merck、 Novartis、 Takeda Pharmaceutical、 Astra Zeneca、 Boehringer Ingelheim、 KOWA、 Kythera、 Fuji yakuhin、 LG Life Science、 Metsubishi Tanabe Pharmaなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

マーケットモニターグローバル社は、脂質代謝異常症治療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別マーケット分析】

世界の脂質代謝異常症治療薬市場：タイプ別、2018年-2023年、2024年-2029年
世界の脂質代謝異常症治療薬市場：タイプ別市場シェア、2022年
・OTC、Rx治療薬

世界の脂質代謝異常症治療薬市場：用途別、2018年-2023年、2024年-2029年
世界の脂質代謝異常症治療薬市場：用途別市場シェア、2022年
・病院、小売薬局

世界の脂質代謝異常症治療薬市場：地域・国別、2018年-2023年、2024年-2029年
世界の脂質代謝異常症治療薬市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競争分析】

また、当レポートは主要な参入企業の分析を提供します。
・主要企業における脂質代謝異常症治療薬のグローバル売上、2018年-2023年
・主要企業における脂質代謝異常症治療薬のグローバル売上シェア、2022年
・主要企業における脂質代謝異常症治療薬のグローバル販売量、2018年-2023年
・主要企業における脂質代謝異常症治療薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業の情報を提示します。
Merck、 Novartis、 Takeda Pharmaceutical、 Astra Zeneca、 Boehringer Ingelheim、 KOWA、 Kythera、 Fuji yakuhin、 LG Life Science、 Metsubishi Tanabe Pharma

*************************************************************

・調査・分析レポートの概要
脂質代謝異常症治療薬市場の定義
市場セグメント
世界の脂質代謝異常症治療薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の脂質代謝異常症治療薬市場規模
世界の脂質代謝異常症治療薬市場規模：2022年 VS 2029年
世界の脂質代謝異常症治療薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの脂質代謝異常症治療薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の脂質代謝異常症治療薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：OTC、Rx治療薬
脂質代謝異常症治療薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院、小売薬局
脂質代謝異常症治療薬の用途別グローバル売上・予測

・地域別市場分析
地域別脂質代謝異常症治療薬市場規模 2022年と2029年
地域別脂質代謝異常症治療薬売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業の情報（企業概要、事業概要、主要製品、売上、ニュースなど）
Merck、 Novartis、 Takeda Pharmaceutical、 Astra Zeneca、 Boehringer Ingelheim、 KOWA、 Kythera、 Fuji yakuhin、 LG Life Science、 Metsubishi Tanabe Pharma
...

Lipid Metabolism Disease Drug is usually used to help lipid metabolism.
This report aims to provide a comprehensive presentation of the global market for Drugs for Lipid Metabolism Disease, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Lipid Metabolism Disease. This report contains market size and forecasts of Drugs for Lipid Metabolism Disease in global, including the following market information:
Global Drugs for Lipid Metabolism Disease Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Drugs for Lipid Metabolism Disease Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Drugs for Lipid Metabolism Disease companies in 2022 (%)
The global Drugs for Lipid Metabolism Disease market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
OTC Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Drugs for Lipid Metabolism Disease include Merck, Novartis, Takeda Pharmaceutical, Astra Zeneca, Boehringer Ingelheim, KOWA, Kythera, Fuji yakuhin and LG Life Science, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Drugs for Lipid Metabolism Disease manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Drugs for Lipid Metabolism Disease Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Drugs for Lipid Metabolism Disease Market Segment Percentages, by Type, 2022 (%)
OTC
Rx Drugs
Global Drugs for Lipid Metabolism Disease Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Drugs for Lipid Metabolism Disease Market Segment Percentages, by Application, 2022 (%)
Hospital
Retail Pharmacy
Global Drugs for Lipid Metabolism Disease Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Drugs for Lipid Metabolism Disease Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Drugs for Lipid Metabolism Disease revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Drugs for Lipid Metabolism Disease revenues share in global market, 2022 (%)
Key companies Drugs for Lipid Metabolism Disease sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Drugs for Lipid Metabolism Disease sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Merck
Novartis
Takeda Pharmaceutical
Astra Zeneca
Boehringer Ingelheim
KOWA
Kythera
Fuji yakuhin
LG Life Science
Metsubishi Tanabe Pharma
Outline of Major Chapters:
Chapter 1: Introduces the definition of Drugs for Lipid Metabolism Disease, market overview.
Chapter 2: Global Drugs for Lipid Metabolism Disease market size in revenue and volume.
Chapter 3: Detailed analysis of Drugs for Lipid Metabolism Disease manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Drugs for Lipid Metabolism Disease in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Drugs for Lipid Metabolism Disease capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Drugs for Lipid Metabolism Disease Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Drugs for Lipid Metabolism Disease Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Drugs for Lipid Metabolism Disease Overall Market Size
2.1 Global Drugs for Lipid Metabolism Disease Market Size: 2022 VS 2029
2.2 Global Drugs for Lipid Metabolism Disease Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Drugs for Lipid Metabolism Disease Sales: 2018-2029
3 Company Landscape
3.1 Top Drugs for Lipid Metabolism Disease Players in Global Market
3.2 Top Global Drugs for Lipid Metabolism Disease Companies Ranked by Revenue
3.3 Global Drugs for Lipid Metabolism Disease Revenue by Companies
3.4 Global Drugs for Lipid Metabolism Disease Sales by Companies
3.5 Global Drugs for Lipid Metabolism Disease Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Drugs for Lipid Metabolism Disease Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Drugs for Lipid Metabolism Disease Product Type
3.8 Tier 1, Tier 2 and Tier 3 Drugs for Lipid Metabolism Disease Players in Global Market
3.8.1 List of Global Tier 1 Drugs for Lipid Metabolism Disease Companies
3.8.2 List of Global Tier 2 and Tier 3 Drugs for Lipid Metabolism Disease Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Drugs for Lipid Metabolism Disease Market Size Markets, 2022 & 2029
4.1.2 OTC
4.1.3 Rx Drugs
4.2 By Type – Global Drugs for Lipid Metabolism Disease Revenue & Forecasts
4.2.1 By Type – Global Drugs for Lipid Metabolism Disease Revenue, 2018-2023
4.2.2 By Type – Global Drugs for Lipid Metabolism Disease Revenue, 2024-2029
4.2.3 By Type – Global Drugs for Lipid Metabolism Disease Revenue Market Share, 2018-2029
4.3 By Type – Global Drugs for Lipid Metabolism Disease Sales & Forecasts
4.3.1 By Type – Global Drugs for Lipid Metabolism Disease Sales, 2018-2023
4.3.2 By Type – Global Drugs for Lipid Metabolism Disease Sales, 2024-2029
4.3.3 By Type – Global Drugs for Lipid Metabolism Disease Sales Market Share, 2018-2029
4.4 By Type – Global Drugs for Lipid Metabolism Disease Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Drugs for Lipid Metabolism Disease Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Retail Pharmacy
5.2 By Application – Global Drugs for Lipid Metabolism Disease Revenue & Forecasts
5.2.1 By Application – Global Drugs for Lipid Metabolism Disease Revenue, 2018-2023
5.2.2 By Application – Global Drugs for Lipid Metabolism Disease Revenue, 2024-2029
5.2.3 By Application – Global Drugs for Lipid Metabolism Disease Revenue Market Share, 2018-2029
5.3 By Application – Global Drugs for Lipid Metabolism Disease Sales & Forecasts
5.3.1 By Application – Global Drugs for Lipid Metabolism Disease Sales, 2018-2023
5.3.2 By Application – Global Drugs for Lipid Metabolism Disease Sales, 2024-2029
5.3.3 By Application – Global Drugs for Lipid Metabolism Disease Sales Market Share, 2018-2029
5.4 By Application – Global Drugs for Lipid Metabolism Disease Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Drugs for Lipid Metabolism Disease Market Size, 2022 & 2029
6.2 By Region – Global Drugs for Lipid Metabolism Disease Revenue & Forecasts
6.2.1 By Region – Global Drugs for Lipid Metabolism Disease Revenue, 2018-2023
6.2.2 By Region – Global Drugs for Lipid Metabolism Disease Revenue, 2024-2029
6.2.3 By Region – Global Drugs for Lipid Metabolism Disease Revenue Market Share, 2018-2029
6.3 By Region – Global Drugs for Lipid Metabolism Disease Sales & Forecasts
6.3.1 By Region – Global Drugs for Lipid Metabolism Disease Sales, 2018-2023
6.3.2 By Region – Global Drugs for Lipid Metabolism Disease Sales, 2024-2029
6.3.3 By Region – Global Drugs for Lipid Metabolism Disease Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Drugs for Lipid Metabolism Disease Revenue, 2018-2029
6.4.2 By Country – North America Drugs for Lipid Metabolism Disease Sales, 2018-2029
6.4.3 US Drugs for Lipid Metabolism Disease Market Size, 2018-2029
6.4.4 Canada Drugs for Lipid Metabolism Disease Market Size, 2018-2029
6.4.5 Mexico Drugs for Lipid Metabolism Disease Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Drugs for Lipid Metabolism Disease Revenue, 2018-2029
6.5.2 By Country – Europe Drugs for Lipid Metabolism Disease Sales, 2018-2029
6.5.3 Germany Drugs for Lipid Metabolism Disease Market Size, 2018-2029
6.5.4 France Drugs for Lipid Metabolism Disease Market Size, 2018-2029
6.5.5 U.K. Drugs for Lipid Metabolism Disease Market Size, 2018-2029
6.5.6 Italy Drugs for Lipid Metabolism Disease Market Size, 2018-2029
6.5.7 Russia Drugs for Lipid Metabolism Disease Market Size, 2018-2029
6.5.8 Nordic Countries Drugs for Lipid Metabolism Disease Market Size, 2018-2029
6.5.9 Benelux Drugs for Lipid Metabolism Disease Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Drugs for Lipid Metabolism Disease Revenue, 2018-2029
6.6.2 By Region – Asia Drugs for Lipid Metabolism Disease Sales, 2018-2029
6.6.3 China Drugs for Lipid Metabolism Disease Market Size, 2018-2029
6.6.4 Japan Drugs for Lipid Metabolism Disease Market Size, 2018-2029
6.6.5 South Korea Drugs for Lipid Metabolism Disease Market Size, 2018-2029
6.6.6 Southeast Asia Drugs for Lipid Metabolism Disease Market Size, 2018-2029
6.6.7 India Drugs for Lipid Metabolism Disease Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Drugs for Lipid Metabolism Disease Revenue, 2018-2029
6.7.2 By Country – South America Drugs for Lipid Metabolism Disease Sales, 2018-2029
6.7.3 Brazil Drugs for Lipid Metabolism Disease Market Size, 2018-2029
6.7.4 Argentina Drugs for Lipid Metabolism Disease Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Drugs for Lipid Metabolism Disease Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Drugs for Lipid Metabolism Disease Sales, 2018-2029
6.8.3 Turkey Drugs for Lipid Metabolism Disease Market Size, 2018-2029
6.8.4 Israel Drugs for Lipid Metabolism Disease Market Size, 2018-2029
6.8.5 Saudi Arabia Drugs for Lipid Metabolism Disease Market Size, 2018-2029
6.8.6 UAE Drugs for Lipid Metabolism Disease Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Merck
7.1.1 Merck Company Summary
7.1.2 Merck Business Overview
7.1.3 Merck Drugs for Lipid Metabolism Disease Major Product Offerings
7.1.4 Merck Drugs for Lipid Metabolism Disease Sales and Revenue in Global (2018-2023)
7.1.5 Merck Key News & Latest Developments
7.2 Novartis
7.2.1 Novartis Company Summary
7.2.2 Novartis Business Overview
7.2.3 Novartis Drugs for Lipid Metabolism Disease Major Product Offerings
7.2.4 Novartis Drugs for Lipid Metabolism Disease Sales and Revenue in Global (2018-2023)
7.2.5 Novartis Key News & Latest Developments
7.3 Takeda Pharmaceutical
7.3.1 Takeda Pharmaceutical Company Summary
7.3.2 Takeda Pharmaceutical Business Overview
7.3.3 Takeda Pharmaceutical Drugs for Lipid Metabolism Disease Major Product Offerings
7.3.4 Takeda Pharmaceutical Drugs for Lipid Metabolism Disease Sales and Revenue in Global (2018-2023)
7.3.5 Takeda Pharmaceutical Key News & Latest Developments
7.4 Astra Zeneca
7.4.1 Astra Zeneca Company Summary
7.4.2 Astra Zeneca Business Overview
7.4.3 Astra Zeneca Drugs for Lipid Metabolism Disease Major Product Offerings
7.4.4 Astra Zeneca Drugs for Lipid Metabolism Disease Sales and Revenue in Global (2018-2023)
7.4.5 Astra Zeneca Key News & Latest Developments
7.5 Boehringer Ingelheim
7.5.1 Boehringer Ingelheim Company Summary
7.5.2 Boehringer Ingelheim Business Overview
7.5.3 Boehringer Ingelheim Drugs for Lipid Metabolism Disease Major Product Offerings
7.5.4 Boehringer Ingelheim Drugs for Lipid Metabolism Disease Sales and Revenue in Global (2018-2023)
7.5.5 Boehringer Ingelheim Key News & Latest Developments
7.6 KOWA
7.6.1 KOWA Company Summary
7.6.2 KOWA Business Overview
7.6.3 KOWA Drugs for Lipid Metabolism Disease Major Product Offerings
7.6.4 KOWA Drugs for Lipid Metabolism Disease Sales and Revenue in Global (2018-2023)
7.6.5 KOWA Key News & Latest Developments
7.7 Kythera
7.7.1 Kythera Company Summary
7.7.2 Kythera Business Overview
7.7.3 Kythera Drugs for Lipid Metabolism Disease Major Product Offerings
7.7.4 Kythera Drugs for Lipid Metabolism Disease Sales and Revenue in Global (2018-2023)
7.7.5 Kythera Key News & Latest Developments
7.8 Fuji yakuhin
7.8.1 Fuji yakuhin Company Summary
7.8.2 Fuji yakuhin Business Overview
7.8.3 Fuji yakuhin Drugs for Lipid Metabolism Disease Major Product Offerings
7.8.4 Fuji yakuhin Drugs for Lipid Metabolism Disease Sales and Revenue in Global (2018-2023)
7.8.5 Fuji yakuhin Key News & Latest Developments
7.9 LG Life Science
7.9.1 LG Life Science Company Summary
7.9.2 LG Life Science Business Overview
7.9.3 LG Life Science Drugs for Lipid Metabolism Disease Major Product Offerings
7.9.4 LG Life Science Drugs for Lipid Metabolism Disease Sales and Revenue in Global (2018-2023)
7.9.5 LG Life Science Key News & Latest Developments
7.10 Metsubishi Tanabe Pharma
7.10.1 Metsubishi Tanabe Pharma Company Summary
7.10.2 Metsubishi Tanabe Pharma Business Overview
7.10.3 Metsubishi Tanabe Pharma Drugs for Lipid Metabolism Disease Major Product Offerings
7.10.4 Metsubishi Tanabe Pharma Drugs for Lipid Metabolism Disease Sales and Revenue in Global (2018-2023)
7.10.5 Metsubishi Tanabe Pharma Key News & Latest Developments
8 Global Drugs for Lipid Metabolism Disease Production Capacity, Analysis
8.1 Global Drugs for Lipid Metabolism Disease Production Capacity, 2018-2029
8.2 Drugs for Lipid Metabolism Disease Production Capacity of Key Manufacturers in Global Market
8.3 Global Drugs for Lipid Metabolism Disease Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Drugs for Lipid Metabolism Disease Supply Chain Analysis
10.1 Drugs for Lipid Metabolism Disease Industry Value Chain
10.2 Drugs for Lipid Metabolism Disease Upstream Market
10.3 Drugs for Lipid Metabolism Disease Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Drugs for Lipid Metabolism Disease Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of Drugs for Lipid Metabolism Disease in Global Market
Table 2. Top Drugs for Lipid Metabolism Disease Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Drugs for Lipid Metabolism Disease Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Drugs for Lipid Metabolism Disease Revenue Share by Companies, 2018-2023
Table 5. Global Drugs for Lipid Metabolism Disease Sales by Companies, (K Units), 2018-2023
Table 6. Global Drugs for Lipid Metabolism Disease Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Drugs for Lipid Metabolism Disease Price (2018-2023) & (USD/Unit)
Table 8. Global Manufacturers Drugs for Lipid Metabolism Disease Product Type
Table 9. List of Global Tier 1 Drugs for Lipid Metabolism Disease Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Drugs for Lipid Metabolism Disease Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Drugs for Lipid Metabolism Disease Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Drugs for Lipid Metabolism Disease Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Drugs for Lipid Metabolism Disease Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Drugs for Lipid Metabolism Disease Sales (K Units), 2018-2023
Table 15. By Type - Global Drugs for Lipid Metabolism Disease Sales (K Units), 2024-2029
Table 16. By Application – Global Drugs for Lipid Metabolism Disease Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Drugs for Lipid Metabolism Disease Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Drugs for Lipid Metabolism Disease Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Drugs for Lipid Metabolism Disease Sales (K Units), 2018-2023
Table 20. By Application - Global Drugs for Lipid Metabolism Disease Sales (K Units), 2024-2029
Table 21. By Region – Global Drugs for Lipid Metabolism Disease Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Drugs for Lipid Metabolism Disease Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Drugs for Lipid Metabolism Disease Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Drugs for Lipid Metabolism Disease Sales (K Units), 2018-2023
Table 25. By Region - Global Drugs for Lipid Metabolism Disease Sales (K Units), 2024-2029
Table 26. By Country - North America Drugs for Lipid Metabolism Disease Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Drugs for Lipid Metabolism Disease Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Drugs for Lipid Metabolism Disease Sales, (K Units), 2018-2023
Table 29. By Country - North America Drugs for Lipid Metabolism Disease Sales, (K Units), 2024-2029
Table 30. By Country - Europe Drugs for Lipid Metabolism Disease Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Drugs for Lipid Metabolism Disease Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Drugs for Lipid Metabolism Disease Sales, (K Units), 2018-2023
Table 33. By Country - Europe Drugs for Lipid Metabolism Disease Sales, (K Units), 2024-2029
Table 34. By Region - Asia Drugs for Lipid Metabolism Disease Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Drugs for Lipid Metabolism Disease Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Drugs for Lipid Metabolism Disease Sales, (K Units), 2018-2023
Table 37. By Region - Asia Drugs for Lipid Metabolism Disease Sales, (K Units), 2024-2029
Table 38. By Country - South America Drugs for Lipid Metabolism Disease Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Drugs for Lipid Metabolism Disease Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Drugs for Lipid Metabolism Disease Sales, (K Units), 2018-2023
Table 41. By Country - South America Drugs for Lipid Metabolism Disease Sales, (K Units), 2024-2029
Table 42. By Country - Middle East & Africa Drugs for Lipid Metabolism Disease Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Drugs for Lipid Metabolism Disease Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Drugs for Lipid Metabolism Disease Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Drugs for Lipid Metabolism Disease Sales, (K Units), 2024-2029
Table 46. Merck Company Summary
Table 47. Merck Drugs for Lipid Metabolism Disease Product Offerings
Table 48. Merck Drugs for Lipid Metabolism Disease Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 49. Merck Key News & Latest Developments
Table 50. Novartis Company Summary
Table 51. Novartis Drugs for Lipid Metabolism Disease Product Offerings
Table 52. Novartis Drugs for Lipid Metabolism Disease Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 53. Novartis Key News & Latest Developments
Table 54. Takeda Pharmaceutical Company Summary
Table 55. Takeda Pharmaceutical Drugs for Lipid Metabolism Disease Product Offerings
Table 56. Takeda Pharmaceutical Drugs for Lipid Metabolism Disease Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 57. Takeda Pharmaceutical Key News & Latest Developments
Table 58. Astra Zeneca Company Summary
Table 59. Astra Zeneca Drugs for Lipid Metabolism Disease Product Offerings
Table 60. Astra Zeneca Drugs for Lipid Metabolism Disease Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 61. Astra Zeneca Key News & Latest Developments
Table 62. Boehringer Ingelheim Company Summary
Table 63. Boehringer Ingelheim Drugs for Lipid Metabolism Disease Product Offerings
Table 64. Boehringer Ingelheim Drugs for Lipid Metabolism Disease Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 65. Boehringer Ingelheim Key News & Latest Developments
Table 66. KOWA Company Summary
Table 67. KOWA Drugs for Lipid Metabolism Disease Product Offerings
Table 68. KOWA Drugs for Lipid Metabolism Disease Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 69. KOWA Key News & Latest Developments
Table 70. Kythera Company Summary
Table 71. Kythera Drugs for Lipid Metabolism Disease Product Offerings
Table 72. Kythera Drugs for Lipid Metabolism Disease Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 73. Kythera Key News & Latest Developments
Table 74. Fuji yakuhin Company Summary
Table 75. Fuji yakuhin Drugs for Lipid Metabolism Disease Product Offerings
Table 76. Fuji yakuhin Drugs for Lipid Metabolism Disease Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 77. Fuji yakuhin Key News & Latest Developments
Table 78. LG Life Science Company Summary
Table 79. LG Life Science Drugs for Lipid Metabolism Disease Product Offerings
Table 80. LG Life Science Drugs for Lipid Metabolism Disease Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 81. LG Life Science Key News & Latest Developments
Table 82. Metsubishi Tanabe Pharma Company Summary
Table 83. Metsubishi Tanabe Pharma Drugs for Lipid Metabolism Disease Product Offerings
Table 84. Metsubishi Tanabe Pharma Drugs for Lipid Metabolism Disease Sales (K Units), Revenue (US$, Mn) and Average Price (USD/Unit) (2018-2023)
Table 85. Metsubishi Tanabe Pharma Key News & Latest Developments
Table 86. Drugs for Lipid Metabolism Disease Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 87. Global Drugs for Lipid Metabolism Disease Capacity Market Share of Key Manufacturers, 2021-2023
Table 88. Global Drugs for Lipid Metabolism Disease Production by Region, 2018-2023 (K Units)
Table 89. Global Drugs for Lipid Metabolism Disease Production by Region, 2024-2029 (K Units)
Table 90. Drugs for Lipid Metabolism Disease Market Opportunities & Trends in Global Market
Table 91. Drugs for Lipid Metabolism Disease Market Drivers in Global Market
Table 92. Drugs for Lipid Metabolism Disease Market Restraints in Global Market
Table 93. Drugs for Lipid Metabolism Disease Raw Materials
Table 94. Drugs for Lipid Metabolism Disease Raw Materials Suppliers in Global Market
Table 95. Typical Drugs for Lipid Metabolism Disease Downstream
Table 96. Drugs for Lipid Metabolism Disease Downstream Clients in Global Market
Table 97. Drugs for Lipid Metabolism Disease Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Drugs for Lipid Metabolism Disease Segment by Type in 2022
Figure 2. Drugs for Lipid Metabolism Disease Segment by Application in 2022
Figure 3. Global Drugs for Lipid Metabolism Disease Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Drugs for Lipid Metabolism Disease Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Drugs for Lipid Metabolism Disease Revenue, 2018-2029 (US$, Mn)
Figure 7. Drugs for Lipid Metabolism Disease Sales in Global Market: 2018-2029 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Drugs for Lipid Metabolism Disease Revenue in 2022
Figure 9. By Type - Global Drugs for Lipid Metabolism Disease Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Drugs for Lipid Metabolism Disease Revenue Market Share, 2018-2029
Figure 11. By Type - Global Drugs for Lipid Metabolism Disease Sales Market Share, 2018-2029
Figure 12. By Type - Global Drugs for Lipid Metabolism Disease Price (USD/Unit), 2018-2029
Figure 13. By Application - Global Drugs for Lipid Metabolism Disease Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Drugs for Lipid Metabolism Disease Revenue Market Share, 2018-2029
Figure 15. By Application - Global Drugs for Lipid Metabolism Disease Sales Market Share, 2018-2029
Figure 16. By Application - Global Drugs for Lipid Metabolism Disease Price (USD/Unit), 2018-2029
Figure 17. By Region - Global Drugs for Lipid Metabolism Disease Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Drugs for Lipid Metabolism Disease Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Drugs for Lipid Metabolism Disease Revenue Market Share, 2018-2029
Figure 20. By Region - Global Drugs for Lipid Metabolism Disease Sales Market Share, 2018-2029
Figure 21. By Country - North America Drugs for Lipid Metabolism Disease Revenue Market Share, 2018-2029
Figure 22. By Country - North America Drugs for Lipid Metabolism Disease Sales Market Share, 2018-2029
Figure 23. US Drugs for Lipid Metabolism Disease Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Drugs for Lipid Metabolism Disease Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Drugs for Lipid Metabolism Disease Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Drugs for Lipid Metabolism Disease Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Drugs for Lipid Metabolism Disease Sales Market Share, 2018-2029
Figure 28. Germany Drugs for Lipid Metabolism Disease Revenue, (US$, Mn), 2018-2029
Figure 29. France Drugs for Lipid Metabolism Disease Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Drugs for Lipid Metabolism Disease Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Drugs for Lipid Metabolism Disease Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Drugs for Lipid Metabolism Disease Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Drugs for Lipid Metabolism Disease Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Drugs for Lipid Metabolism Disease Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Drugs for Lipid Metabolism Disease Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Drugs for Lipid Metabolism Disease Sales Market Share, 2018-2029
Figure 37. China Drugs for Lipid Metabolism Disease Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Drugs for Lipid Metabolism Disease Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Drugs for Lipid Metabolism Disease Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Drugs for Lipid Metabolism Disease Revenue, (US$, Mn), 2018-2029
Figure 41. India Drugs for Lipid Metabolism Disease Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Drugs for Lipid Metabolism Disease Revenue Market Share, 2018-2029
Figure 43. By Country - South America Drugs for Lipid Metabolism Disease Sales Market Share, 2018-2029
Figure 44. Brazil Drugs for Lipid Metabolism Disease Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Drugs for Lipid Metabolism Disease Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Drugs for Lipid Metabolism Disease Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Drugs for Lipid Metabolism Disease Sales Market Share, 2018-2029
Figure 48. Turkey Drugs for Lipid Metabolism Disease Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Drugs for Lipid Metabolism Disease Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Drugs for Lipid Metabolism Disease Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Drugs for Lipid Metabolism Disease Revenue, (US$, Mn), 2018-2029
Figure 52. Global Drugs for Lipid Metabolism Disease Production Capacity (K Units), 2018-2029
Figure 53. The Percentage of Production Drugs for Lipid Metabolism Disease by Region, 2022 VS 2029
Figure 54. Drugs for Lipid Metabolism Disease Industry Value Chain
Figure 55. Marketing Channels

※参考情報

脂質代謝異常症治療薬は、体内の脂質の代謝に関連する異常を治療するために使用される薬剤群を指します。脂質代謝異常症とは、脂質の合成や分解、輸送に関与するメカニズムに異常が生じ、血中の脂質濃度が正常範囲から逸脱する状態を指します。最も一般的な形態は高脂血症であり、心血管疾患を含むさまざまな健康問題のリスクを高めます。

脂質代謝異常症治療薬には、いくつかの種類があり、それぞれ異なるメカニズムで脂質の調節を行います。これらの薬剤は、主に以下の特徴を持っています。

まず、脂質代謝異常症治療薬の主要な目的は、血中のコレステロールやトリグリセリドのレベルを低下させることです。コレステロールには、悪玉コレステロール（LDL）と善玉コレステロール（HDL）があり、高LDLコレステロールは心血管イベントのリスクを高めます。薬剤はこれらの脂質のバランスを整え、心臓病や脳卒中の予防に寄与します。

脂質代謝異常症治療薬の代表的な種類として、スタチン類、フィブラート類、ニコチン酸誘導体、胆汁酸吸着薬などがあります。スタチン類は、HMG-CoA還元酵素を阻害することで肝臓におけるコレステロールの合成を抑制し、LDLコレステロールを効果的に低下させます。代表的なスタチンにはアトルバスタチンやシンバスタチンがあります。これらの薬剤は心血管疾患の予防に広く使用されており、長期的な治療効果が確認されています。

フィブラート類は、主にトリグリセリドの低下に寄与する薬剤であり、ペルオキシソーム増殖因子活性化受容体（PPAR）に作用します。これにより脂質の酸化が促進され、LDLコレステロールが減少する補助効果も持っています。ニコチン酸誘導体は、脂肪酸の動員を抑制し、HDLコレステロールを増加させる効果がありますが、副作用として顔面紅潮が生じることがあるため、使用には注意が必要です。

胆汁酸吸着薬は、腸内で胆汁酸と結合することで、コレステロールの再吸収を阻害し、肝臓が新たにコレステロールを合成するよう促します。このメカニズムによって、LDLコレステロールが減少します。

これらの薬剤の用途は、単独での使用はもちろん、複数種類の薬剤を併用することで、相乗効果を高めることが可能です。特に、高リスク群や治療抵抗性の患者においては、コンビネーション療法が有効とされています。

脂質代謝異常症治療薬の使用にあたっては、個々の患者に応じた適切な管理が必要です。副作用のリスクに注意しながら、定期的な血液検査を行い、脂質レベルのモニタリングを行います。また、生活習慣の改善も併せて行うことが、薬剤の効果を最大限に引き出します。食事の見直しや運動、禁煙などが推奨される具体的な方法です。

さらに、脂質代謝異常症治療薬に関連する技術も進化しています。新たに開発された薬剤が登場しており、特にPCSK9阻害薬は、革新的な治療選択肢として注目されています。PCSK9は、肝臓におけるLDL受容体の分解を助けるタンパク質ですが、この機能を阻害することで、LDLコレステロールのクリアランスが向上します。これにより、従来の薬剤では十分な効果が得られなかった患者に対しても治療効果が期待できます。

今後の研究により、脂質代謝異常症に関連する新しい薬剤や治療法が開発されることが期待されます。例えば、遺伝子治療やナノテクノロジーを用いた革新的なアプローチが進行中で、これによりさらに効果的な治療が可能になる可能性があります。脂質代謝異常症治療薬の発展は、心血管疾患の予防や治療において重大な影響を及ぼすことが期待されています。

最後に、脂質代謝異常症に対するアプローチは、一人ひとりの患者の状態に応じた個別化医療が求められる時代に入っています。薬剤の選択や生活習慣の改善策は、専門の医療従事者と連携しながら進めることが重要です。脂質代謝異常症治療薬は、その適切な使用と相まって、生活の質の向上に寄与し、健康を守るための重要な役割を果たしています。心血管疾患のリスクを軽減し、健康で充実した生活を維持するために、これらの薬剤に関する理解を深めることが求められています。

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 脂質代謝異常症治療薬の世界市場見通し2023年-2029年(Drugs for Lipid Metabolism Disease Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

脂質代謝異常症治療薬の世界市場見通し2023年-2029年

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp